Phase 3 Readout~month

Phase 3 Topline: A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabi

Name: Phase 3 Topline: A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabi
Start: 2028-02-01

February 1, 2028

Company: BELITE BIO, INC (BLTE)
Drug: stargardt
Indication: STGD1; Stargardt Disease 1

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabi — BLTE Phase 3 Readout | BioSniper